Cabozantinib vs. Anlotinib: Who should I choose?

In the field of targeted therapy, Cabozantinib and Anlotinib are both multi-target tyrosine kinase inhibitors, but there are obvious differences in indications, mechanisms of action, clinical applications and accessibility. The original drug Cabozantinib was originally developed in the United States. It mainly targets a variety of solid tumors such as advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and differentiated thyroid cancer (DTC). It can simultaneously inhibit multiple signaling pathways such as VEGFR, MET, and AXL, thereby inhibiting tumor angiogenesis, invasion and metastasis. This multi-target feature gives cabozantinib unique advantages in controlling tumor progression, angiogenesis and drug resistance mechanisms, especially in patients who have previously failed VEGFR inhibitor treatment, and still show significant efficacy.

Anlotinib is an oral small molecule multi-target tyrosine kinase inhibitor independently developed in China. Its main targets includeVEGFR, FGFR, PDGFR and c-Kit. Its clinical advantage lies in its wide range of indications, covering second-line or third-line treatment of non-small cell lung cancer (NSCLC), soft tissue sarcoma, thyroid cancer, and advanced lung cancer. At the same time, anlotinib has good accessibility and medical insurance coverage in China, is convenient for oral administration, and is relatively economical for long-term maintenance treatment, which can meet the actual treatment needs of Chinese patients. The side effects spectrum of anlotinib is relatively mild, and side effects such as elevated blood pressure and hand-foot syndrome can be controlled through dose adjustment and auxiliary drug management.

From a pharmacological mechanism perspective, cabozantinib's MET and AXL inhibitory effects give it potential advantages in drug resistance and tumor microenvironment regulation. For example, cabozantinib significantly delayed tumor progression and improved progression-free survival in patients with advanced renal cell carcinoma and hepatocellular carcinoma. At the same time, cabozantinib also has a stronger inhibitory effect on tumor-related angiogenesis, which may make it more effective in advanced tumors or highly invasive lesions. Although anlotinib is slightly inferior in MET/AXL inhibition, its inhibition of VEGFR and FGFR is more concentrated, and it also has a good effect on angiogenesis-dependent tumors.

In terms of clinical accessibility and economy, anlotinib has obvious advantages in the domestic market. Cabozantinib is not yet widely available in China. Access channels are relatively limited and the price is high, which may pose an obstacle to patients with limited financial ability. In contrast, anlotinib can be reimbursed directly through medical insurance in China, and its long-term treatment is more sustainable. For clinicians and patients, it can be used as the first-choice targeted drug, especially in the multi-line treatment of advanced lung cancer and solid tumors.

To sum up, the treatment choice between cabozantinib and anlotinib is not a simple one, but it needs to be comprehensively judged based on the patient's tumor type, previous treatment experience, drug resistance mechanism, economic conditions and medical insurance coverage. For patients with tumors that require simultaneous inhibition of multiple targets, are resistant, or have high-risk tumors, cabozantinib may be slightly better in efficacy; while for domestic patients, especially those with higher economic and accessibility requirements, anlotinib is a more practical and sustainable choice.

Reference:https://en.wikipedia.org/wiki/Cabozantinib